Neena Brizmohun
Deputy editor of Pink Sheet/Scrip/Medtech Insight. Interested in science, pharma and medtech. All views expressed are my own.
Articles
-
5 days ago |
insights.citeline.com | Neena Brizmohun
New EU FilingsLinerixibat, GSK's treatment for cholestatic pruritus in patients with primary biliary cholangitis, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
-
1 week ago |
insights.citeline.com | Neena Brizmohun
EMA Explores How To Support Drug Development For High Unmet Need Disorder Scleroderma While treatments for scleroderma are in development, none are approved for the condition that is associated with high morbidity and mortality. The European Medicines Agency says guidance on how to design development programs for the disorder is needed. There are no approved medicines for scleroderma (Shutterstock)
-
1 week ago |
insights.citeline.com | Neena Brizmohun
Not Over Yet: Eisai And Lilly To Appeal England’s ‘Flawed’ Refusal To Fund Leqembi And KisunlaEisai and Lilly explain why they disagree with today’s conclusion by the health technology assessment institute, NICE, that the benefits of their respective drugs for Alzheimer’s disease are too small to justify the additional cost to the National Health Service. Patients in England will not be able to access the Alzheimer's treatments Leqembi and Kisunla via the NHS (Shutterstock)
-
1 week ago |
insights.citeline.com | Neena Brizmohun
Lerodalcibep & First Generic Palbociclib Among 10 New EMA Filings18 Jun 2025Lerodalcibep and palbociclib are among the latest new drugs that the European Medicines Agency has started to review for potential EU marketing authorization. The EMA is reviewing marketing applications for new drugs (Shutterstock)
-
1 week ago |
insights.citeline.com | Neena Brizmohun
Canada Joins Global Push To Drop Costly Clinical Trials For Biosimilars Health Canada’s proposal to no longer require biosimilar manufacturers to prove the safety and efficacy of their product through Phase III clinical trials marks a pivotal change in Canada’s regulatory approach. Health Canada is revising its guidance on submission requirements for biosimilar drugs (Shutterstock)
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →X (formerly Twitter)
- Followers
- 928
- Tweets
- 963
- DMs Open
- No
We’re really excited for tomorrow’s webinar on useful tactics for streamlining pharmacovigilance and medical information processes in today's regulatory landscape. Follow the link for more information and to register your attendance https://t.co/QmznXZRXU7
RT @ScripRegVibha: Looking forward to the DIA Europe 2022 meeting tomorrow. Some great sessions listed on the agenda, especially on EU Clin…
RT @ScripRegMaureen: This free-to-view article from @PharmaPinkSheet sister publication @Genericbulletin highlights the off-patent industry…
